Skip to content

CINVANTI Situation Assessment

Questions for CINVANTI Users

Thank you for agreeing to participate in this short survey which aims to capture your feelings on the opportunity for CINVANTI based on what is happening with key accounts that you cover. We’ll ask you to speak to accounts that you cover when filling out the questions below and make sure to specify so that you can answer the questions accurately.

Please consider your accounts that have purchased CINVANTI in Q1 of 2019 when answering the questions on this page.
1.Please list an account that purchased CINVANTI in Q1 of 2019 that is representative of your purchasing accounts
2.Within this account, what is the current share of each of the following IV NK1 receptor antagonists used to prophylactically treat patients (defined as anti-emetics administered on the same day of chemo) receiving highly emetogenic (HEC) and moderately emetogenic (MEC) chemotherapy regimens?
3.What were the key product attributes that led to the adoption of CINVANTI in this account? ​[Allocate 100 points across options to show importance]
4.What are the drivers for this account’s decision to use Cinvanti IV? ​[Allocate 100 points across options shown below]
5.If you allocated points to other, please indicate what driver you meant. If you did not select ‘other,’ please respond with N/A.
6.How has the flexibility of CINVANTI IV Push Route of Administration changed this account’s share of CINVANTI compared to other NK1s?
7.Since IV Akynzeo has begun to increase its value offering (i.e. NCR around $200 per unit), what has happened to this account's CINVANTI market share?
8.When Generic IV Emend (fosaprepitant) enters the market, what we call the “arbitrage,” what will happen to this account's CINVANTI market share?  

Fosaprepitant “arbitrage” is the time period following generic entry where the reimbursement (ASP + 4.3%) for generic fosaprepitant is the same as branded Emend IV (fosaprepitant) reimbursement (same J-code) while the acquisition cost of the generic is significantly lower than the brand creating a short term economic opportunity. Over time the reimbursement for generic fosaprepitant will drop with the increased utilization of the lower priced generics and the temporary economic opportunity disappears.
9.What will this account's share of CINVANTI be during the Fosaprepitant arbitrage? 
10.Do we expect this account to continue to purchase CINVANTI through the Fosaprepitant generic arbitrage?
11.Why should we expect to retain business from this account during Fosaprepitant arbitrage?​ If you answered ‘No’ on the last question, please allocate 100 points to ‘this account will no longer use CINVANTI.’

[Allocate 100 points across options to show importance]
12.When the Fosaprepitant “arbitrage” period ends, what will happen to this account’s CINVANTI share?
13.What will this account's share of CINVANTI be post arbitrage? If you answered ‘They will not switch back to CINVANTI’ on the last question, please put 0 for expected CINVANTI share
Current Progress,
0 of 35 answered